Prostanoid receptor EP1 expression in breast cancer

Mangesh A. Thorat, Akira Morimiya, Sanjana Mehrotra, Raymond Konger, Sunil Badve

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Cyclooxygenase enzymes play an important role in carcinogenesis, and increased expression of cyclooxygenase enzymes has been reported in cancers arising at a number of different sites. Most, if not all of these actions are thought to be mediated by prostaglandin E2 (PGE2). The actions of PGE2 are mediated via four main prostanoid receptors, designated EP1, EP2, EP3 and EP4, based on their different pharmacological properties and secondary messenger pathways. Recently, expression of EP1 has been reported in rat mammary gland and the inhibition of this receptor has been documented to have chemopreventive effect in this animal model. EP1 has also been shown to decrease the incidence of colon cancer in mouse models. In this study, we analysed the expression of EP1 in normal and malignant breast tissues. Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses. Expression was also analysed by immunohistochemistry in normal breast tissues and in 89 cases of breast cancer. Semiquantitative analysis of the staining was performed. The data were compared with and correlated with other prognostic factors like tumour size, tumour grade, lymph node status, oestrogen receptor, progesterone receptor (PR), HER2/neu and cyclooxygenase-2. EP1 expression was demonstrated in human breast cancer by immunohistochemistry. Expression of EP1 was seen both in the cytoplasm and/or in the nuclear membrane in majority of cases. Nuclear EP1 expression correlated with PR (P=0.032) and inversely with node positivity (P=0.025). However, EP1 expression did not correlate with expression of cyclooxygenase-2 (P=0.059). Expression of EP1 is frequently seen in human breast cancers. Nuclear expression of EP1 correlates with good prognosis markers like node negative status and PR expression.

Original languageEnglish
Pages (from-to)15-21
Number of pages7
JournalModern Pathology
Volume21
Issue number1
DOIs
StatePublished - Jan 2008

Fingerprint

Receptors, Prostaglandin E, EP1 Subtype
Progesterone Receptors
Breast Neoplasms
Cyclooxygenase 2
Prostaglandin-Endoperoxide Synthases
Dinoprostone
Breast
Immunohistochemistry
Neoplasms
Nuclear Envelope
Enzymes
Human Mammary Glands
Reverse Transcriptase Polymerase Chain Reaction
Estrogen Receptors
Colonic Neoplasms
Carcinogenesis
Cytoplasm
Animal Models
Lymph Nodes
Western Blotting

Keywords

  • Breast cancer
  • Cyclooxygenase
  • EP1 receptor
  • Immunohistochemistry
  • PGE2
  • Prostanoid receptor

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Prostanoid receptor EP1 expression in breast cancer. / Thorat, Mangesh A.; Morimiya, Akira; Mehrotra, Sanjana; Konger, Raymond; Badve, Sunil.

In: Modern Pathology, Vol. 21, No. 1, 01.2008, p. 15-21.

Research output: Contribution to journalArticle

Thorat, Mangesh A. ; Morimiya, Akira ; Mehrotra, Sanjana ; Konger, Raymond ; Badve, Sunil. / Prostanoid receptor EP1 expression in breast cancer. In: Modern Pathology. 2008 ; Vol. 21, No. 1. pp. 15-21.
@article{605ea916a5b649acacdcdc2bb7622649,
title = "Prostanoid receptor EP1 expression in breast cancer",
abstract = "Cyclooxygenase enzymes play an important role in carcinogenesis, and increased expression of cyclooxygenase enzymes has been reported in cancers arising at a number of different sites. Most, if not all of these actions are thought to be mediated by prostaglandin E2 (PGE2). The actions of PGE2 are mediated via four main prostanoid receptors, designated EP1, EP2, EP3 and EP4, based on their different pharmacological properties and secondary messenger pathways. Recently, expression of EP1 has been reported in rat mammary gland and the inhibition of this receptor has been documented to have chemopreventive effect in this animal model. EP1 has also been shown to decrease the incidence of colon cancer in mouse models. In this study, we analysed the expression of EP1 in normal and malignant breast tissues. Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses. Expression was also analysed by immunohistochemistry in normal breast tissues and in 89 cases of breast cancer. Semiquantitative analysis of the staining was performed. The data were compared with and correlated with other prognostic factors like tumour size, tumour grade, lymph node status, oestrogen receptor, progesterone receptor (PR), HER2/neu and cyclooxygenase-2. EP1 expression was demonstrated in human breast cancer by immunohistochemistry. Expression of EP1 was seen both in the cytoplasm and/or in the nuclear membrane in majority of cases. Nuclear EP1 expression correlated with PR (P=0.032) and inversely with node positivity (P=0.025). However, EP1 expression did not correlate with expression of cyclooxygenase-2 (P=0.059). Expression of EP1 is frequently seen in human breast cancers. Nuclear expression of EP1 correlates with good prognosis markers like node negative status and PR expression.",
keywords = "Breast cancer, Cyclooxygenase, EP1 receptor, Immunohistochemistry, PGE2, Prostanoid receptor",
author = "Thorat, {Mangesh A.} and Akira Morimiya and Sanjana Mehrotra and Raymond Konger and Sunil Badve",
year = "2008",
month = "1",
doi = "10.1038/modpathol.3800970",
language = "English",
volume = "21",
pages = "15--21",
journal = "Modern Pathology",
issn = "0893-3952",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Prostanoid receptor EP1 expression in breast cancer

AU - Thorat, Mangesh A.

AU - Morimiya, Akira

AU - Mehrotra, Sanjana

AU - Konger, Raymond

AU - Badve, Sunil

PY - 2008/1

Y1 - 2008/1

N2 - Cyclooxygenase enzymes play an important role in carcinogenesis, and increased expression of cyclooxygenase enzymes has been reported in cancers arising at a number of different sites. Most, if not all of these actions are thought to be mediated by prostaglandin E2 (PGE2). The actions of PGE2 are mediated via four main prostanoid receptors, designated EP1, EP2, EP3 and EP4, based on their different pharmacological properties and secondary messenger pathways. Recently, expression of EP1 has been reported in rat mammary gland and the inhibition of this receptor has been documented to have chemopreventive effect in this animal model. EP1 has also been shown to decrease the incidence of colon cancer in mouse models. In this study, we analysed the expression of EP1 in normal and malignant breast tissues. Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses. Expression was also analysed by immunohistochemistry in normal breast tissues and in 89 cases of breast cancer. Semiquantitative analysis of the staining was performed. The data were compared with and correlated with other prognostic factors like tumour size, tumour grade, lymph node status, oestrogen receptor, progesterone receptor (PR), HER2/neu and cyclooxygenase-2. EP1 expression was demonstrated in human breast cancer by immunohistochemistry. Expression of EP1 was seen both in the cytoplasm and/or in the nuclear membrane in majority of cases. Nuclear EP1 expression correlated with PR (P=0.032) and inversely with node positivity (P=0.025). However, EP1 expression did not correlate with expression of cyclooxygenase-2 (P=0.059). Expression of EP1 is frequently seen in human breast cancers. Nuclear expression of EP1 correlates with good prognosis markers like node negative status and PR expression.

AB - Cyclooxygenase enzymes play an important role in carcinogenesis, and increased expression of cyclooxygenase enzymes has been reported in cancers arising at a number of different sites. Most, if not all of these actions are thought to be mediated by prostaglandin E2 (PGE2). The actions of PGE2 are mediated via four main prostanoid receptors, designated EP1, EP2, EP3 and EP4, based on their different pharmacological properties and secondary messenger pathways. Recently, expression of EP1 has been reported in rat mammary gland and the inhibition of this receptor has been documented to have chemopreventive effect in this animal model. EP1 has also been shown to decrease the incidence of colon cancer in mouse models. In this study, we analysed the expression of EP1 in normal and malignant breast tissues. Expression of EP1 was analysed in breast (benign and cancer) cell lines by reverse-transcriptase polymerase chain reaction and by western blot analyses. Expression was also analysed by immunohistochemistry in normal breast tissues and in 89 cases of breast cancer. Semiquantitative analysis of the staining was performed. The data were compared with and correlated with other prognostic factors like tumour size, tumour grade, lymph node status, oestrogen receptor, progesterone receptor (PR), HER2/neu and cyclooxygenase-2. EP1 expression was demonstrated in human breast cancer by immunohistochemistry. Expression of EP1 was seen both in the cytoplasm and/or in the nuclear membrane in majority of cases. Nuclear EP1 expression correlated with PR (P=0.032) and inversely with node positivity (P=0.025). However, EP1 expression did not correlate with expression of cyclooxygenase-2 (P=0.059). Expression of EP1 is frequently seen in human breast cancers. Nuclear expression of EP1 correlates with good prognosis markers like node negative status and PR expression.

KW - Breast cancer

KW - Cyclooxygenase

KW - EP1 receptor

KW - Immunohistochemistry

KW - PGE2

KW - Prostanoid receptor

UR - http://www.scopus.com/inward/record.url?scp=37549004432&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37549004432&partnerID=8YFLogxK

U2 - 10.1038/modpathol.3800970

DO - 10.1038/modpathol.3800970

M3 - Article

VL - 21

SP - 15

EP - 21

JO - Modern Pathology

JF - Modern Pathology

SN - 0893-3952

IS - 1

ER -